Alpha Tau Medical Ltd. (DRTS) Cash Flow Statement

The substantial divergence between net income and operating cash flow suggests that non-cash expenses and working capital movements are not sufficient to bridge the gap, indicating that the company's cash burn is accelerating faster than its accounting losses imply. Investors should monitor this ratio closely, as it suggests that the underlying clinical development activities are becoming increasingly capital-intensive.

The negative FCF trajectory confirms that the company is in a deep cash-burn phase with no immediate prospect of self-funding through operations. This trend warrants further investigation into the timing of future capital raises, as the current burn rate appears to exceed the remaining liquidity runway.

This level of capital intensity is typical for firms building proprietary nuclear supply chains, yet it places additional pressure on the company's already strained liquidity. The investment in fixed assets suggests that management is prioritizing long-term infrastructure over short-term cash preservation, which may be a necessary but risky trade-off.

While this positive working capital adjustment helps mitigate the immediate cash outflow, it should not be interpreted as a sign of operational efficiency. Given the pre-revenue status of the firm, such fluctuations are likely driven by timing differences in vendor payments or clinical trial logistics rather than sustainable improvements in cash management.